PortfoliosLab logoPortfoliosLab logo
GILD vs. CI
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GILD vs. CI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Gilead Sciences, Inc. (GILD) and Cigna Corporation (CI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GILD achieves a 5.83% return, which is significantly lower than CI's 6.37% return. Over the past 10 years, GILD has underperformed CI with an annualized return of 7.71%, while CI has yielded a comparatively higher 9.53% annualized return.


GILD

1D
-0.02%
1M
-5.24%
YTD
5.83%
6M
7.86%
1Y
20.04%
3Y*
23.34%
5Y*
18.21%
10Y*
7.71%

CI

1D
3.14%
1M
3.25%
YTD
6.37%
6M
10.29%
1Y
-4.86%
3Y*
5.21%
5Y*
4.73%
10Y*
9.53%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GILD vs. CI - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GILD
Gilead Sciences, Inc.
5.83%36.59%18.68%-1.99%23.63%29.95%-6.70%7.88%-9.92%2.96%
CI
Cigna Corporation
6.37%1.72%-6.27%-7.97%46.68%12.29%1.83%7.70%-6.46%52.29%

Correlation

The correlation between GILD and CI is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.22

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (5Y)
Calculated over the trailing 5-year period

0.28

Correlation (10Y)
Calculated over the trailing 10-year period

0.29

Correlation (All Time)
Calculated using the full available price history since Jan 23, 1992

0.25

Fundamentals

Market Cap

GILD:

$161.97B

CI:

$76.43B

EPS

GILD:

$7.35

CI:

$23.59

PE Ratio

GILD:

17.57

CI:

12.27

PEG Ratio

GILD:

0.04

CI:

0.71

PS Ratio

GILD:

5.45

CI:

0.28

PB Ratio

GILD:

6.89

CI:

1.81

Total Revenue (TTM)

GILD:

$29.74B

CI:

$277.94B

Gross Profit (TTM)

GILD:

$18.74B

CI:

$19.38B

EBITDA (TTM)

GILD:

$12.88B

CI:

$10.03B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GILD vs. CI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GILD
GILD Risk / Return Rank: 6363
Overall Rank
GILD Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
GILD Sortino Ratio Rank: 6161
Sortino Ratio Rank
GILD Omega Ratio Rank: 5757
Omega Ratio Rank
GILD Calmar Ratio Rank: 6464
Calmar Ratio Rank
GILD Martin Ratio Rank: 6565
Martin Ratio Rank

CI
CI Risk / Return Rank: 3434
Overall Rank
CI Sharpe Ratio Rank: 3535
Sharpe Ratio Rank
CI Sortino Ratio Rank: 3131
Sortino Ratio Rank
CI Omega Ratio Rank: 3131
Omega Ratio Rank
CI Calmar Ratio Rank: 3535
Calmar Ratio Rank
CI Martin Ratio Rank: 3636
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GILD vs. CI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Gilead Sciences, Inc. (GILD) and Cigna Corporation (CI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GILDCIDifference
Sharpe ratioReturn per unit of total volatility

+0.91

Sortino ratioReturn per unit of downside risk

+1.27

Omega ratioGain probability vs. loss probability

1.15

1.00

+0.14

Calmar ratioReturn relative to maximum drawdown

1.14

-0.18

+1.32

Martin ratioReturn relative to average drawdown

2.82

-0.34

+3.15

GILD vs. CI - Sharpe Ratio Comparison

The current GILD Sharpe Ratio is 0.77, which is higher than the CI Sharpe Ratio of -0.15. The chart below compares the historical Sharpe Ratios of GILD and CI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


GILDCIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.77

-0.15

+0.91

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.76

0.17

+0.59

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.30

0.31

-0.01

Sharpe Ratio (All Time)

Calculated using the full available price history

0.39

0.34

+0.04

Drawdowns

GILD vs. CI - Drawdown Comparison

The maximum GILD drawdown since its inception was -70.83%, smaller than the maximum CI drawdown of -84.34%. Use the drawdown chart below to compare losses from any high point for GILD and CI.


Loading charts...

Drawdown Indicators


GILDCIDifference

Max Drawdown

Largest peak-to-trough decline

-70.83%

-84.34%

+13.51%

Max Drawdown (1Y)

Largest decline over 1 year

-17.65%

-26.54%

+8.89%

Max Drawdown (3Y)

Largest decline over 3 years

-26.59%

-32.10%

+5.51%

Max Drawdown (5Y)

Largest decline over 5 years

-26.59%

-32.10%

+5.51%

Max Drawdown (10Y)

Largest decline over 10 years

-30.47%

-42.47%

+12.00%

Current Drawdown

Current decline from peak

-16.63%

-18.21%

+1.58%

Average Drawdown

Average peak-to-trough decline

-22.16%

-18.82%

-3.34%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.13%

14.51%

-7.38%

Volatility

GILD vs. CI - Volatility Comparison

The current volatility for Gilead Sciences, Inc. (GILD) is 6.88%, while Cigna Corporation (CI) has a volatility of 9.35%. This indicates that GILD experiences smaller price fluctuations and is considered to be less risky than CI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GILDCIDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.88%

9.35%

-2.47%

Volatility (6M)

Calculated over the trailing 6-month period

18.53%

18.86%

-0.33%

Volatility (1Y)

Calculated over the trailing 1-year period

26.31%

33.18%

-6.87%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

24.02%

28.43%

-4.41%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

25.48%

30.75%

-5.27%

Dividends

GILD vs. CI - Dividend Comparison

GILD's dividend yield for the trailing twelve months is around 2.47%, more than CI's 2.12% yield.


PositionTTM20252024202320222021202020192018201720162015
CI
Cigna Corporation
2.12%2.19%2.03%1.64%1.35%1.74%0.02%0.02%0.02%0.02%0.03%0.03%
GILD
Gilead Sciences, Inc.
2.47%2.57%3.33%3.70%3.40%3.91%4.67%3.88%3.65%2.90%2.57%1.27%

Financials

GILD vs. CI - Financials Comparison

This section allows you to compare key financial metrics between Gilead Sciences, Inc. and Cigna Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


10.00B20.00B30.00B40.00B50.00B60.00B70.00B20222023202420252026
6.96B
68.49B
(GILD) Total Revenue
(CI) Total Revenue
Values in USD except per share items

GILD vs. CI - Profitability Comparison

The chart below illustrates the profitability comparison between Gilead Sciences, Inc. and Cigna Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20222023202420252026
1.1%
0
Portfolio components
GILD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported a gross profit of 79.20M and revenue of 6.96B. Therefore, the gross margin over that period was 1.1%.

CI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cigna Corporation reported a gross profit of 0.00 and revenue of 68.49B. Therefore, the gross margin over that period was 0.0%.

GILD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported an operating income of 2.59B and revenue of 6.96B, resulting in an operating margin of 37.2%.

CI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cigna Corporation reported an operating income of 2.36B and revenue of 68.49B, resulting in an operating margin of 3.4%.

GILD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Gilead Sciences, Inc. reported a net income of 2.02B and revenue of 6.96B, resulting in a net margin of 29.0%.

CI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cigna Corporation reported a net income of 1.65B and revenue of 68.49B, resulting in a net margin of 2.4%.


Frequently Asked Questions


GILD and CI have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CI has higher volatility (9.35%) compared to GILD (6.88%). In terms of maximum drawdown, GILD dropped -70.83% vs CI's -84.34%.

GILD currently has the higher Sharpe Ratio (0.77 vs -0.15), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GILD and CI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer